Update on aromatase inhibitors in breast cancer

Current Opinion in Obstetrics and Gynecology

Volumn 18, Issue 1, 2006, Pages 41-46

  Gould, Richard E ^a   Garcia, Agustin A ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Premiere Oncology   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Hormonal therapy; Review

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; MEGESTROL ACETATE; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE;

ADVANCED CANCER; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG MECHANISM; DRUG TOLERABILITY; FRACTURE; HEART INFARCTION; HOT FLUSH; HUMAN; METASTASIS; MYALGIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VAGINA BLEEDING;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; POSTMENOPAUSE; TAMOXIFEN;

EID: 33646475272     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000192973.54105.86     Document Type: Review

References (36)

1. Beatson GW. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2:104.
2. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94:606-616.
3. Endogenous Hormones and Breast Cancer Collaborative Group. Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. Cancer Epidemiol Biomarkers Prev 2003; 12: 1457-1461.
4. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-1618.
5. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003; 86:225-230.
6. Bonneterre J, Coppens H, Mauriac L, et al. Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. Eur J Cancer Clin Oncol 1985; 21:1153-1158.
7. Carella MJ, Dimitrov NV, Gossain VV, et al. Adrenal effects of low-dose aminoglutethimide when used alone in postmenopausal women with advanced breast cancer. Metabolism 1994; 43:723-727.
8. Njar VC, Brodie AM. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 1999; 58:233-255.
9. Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 1989; 16:83-93.
10. Brodie AM, Njar VC. Aromatase inhibitors and their application in breast cancer treatment. Steroids 2000; 65:171-179.
11. Geisler J, King N, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized cross over study. J Clin Oncol 2002; 20:751-757.
12. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998; 4:2089-2093.
13. Jonat W, Howell A, Blomqvist C, et al. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32A:404-412.
14. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancer. Arimidex Study Group. Cancer 1997; 79:730-739.
15. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998; 83: 1142-1152.
16. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared to megestrol acetate. J Clin Oncol 1998; 16:453-461.
17. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19:3357-3366.
18. Kauffman M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18:1399-1411.
19. Bonneterre J, Thurlimann B, Tobertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 2000; 18:3748-3757.
20. Nabholtz JM, Buzdar A, Pollack M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18:3758-3767.
21. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247-2258.
22. Nabholtz JM, Bonneterre J, Buzdar A, et al. Anastrozole (arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003; 29: 1684-1689.
23. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596-2606.
24. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21:2101-2109.
25. Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients - a randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 2004; 23:6a. Early results of a randomized trial comparing first-line exemestane with tamoxifen in metastatic breast cancer show improved efficacy and tolerability for exemestane.
26. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 2002; 359:2131-2139.
27. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62. Updated results of front-line anastrozole or tamoxifen in the adjuvant setting with a median follow-up of 68 months show continuation of previous DFS benefit.
28. Thurlimann BJ, Keshaviah A, Mouridsen H, et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol 2005; 23s:6s. Early results of up-front adjuvant letrozole compared with tamoxifen improving DFS but showing an increase in the number of cardiovascular events.
29. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092. Randomized trial of sequential tamoxifen to exemestane showing DFS benefit over tamoxifen alone for 5 years.
30. Coombes RC, Hall E, Snowdon CF, et al. The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. Breast Cancer Res Treat 2004; 88s:S7. Updated results for the Intergroup Exemestane Study showing a preserved improvement of DFS and a stronger trend towards improved overall survival.
31. Jakesz R, Kaufmann M, Gnant M, et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3123 women enrolled in ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004; 88s:S7. Randomized study of sequential tamoxifen to anastrozole showing improved DFS over tamoxifen alone for 5 years.
32. Boccardo FM, Rubagotti A, Puntoni M, et al. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. J Clin Oncol 2005; 23s:10s. Small randomized study of sequential tamoxifen to anastrozole showing improved DFS over treatment with tamoxifen alone for 5 years.
33. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-1802.
34. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozale following tamoxifen as extended therapy in receptor-positve breast cancer: update findings from NCLC CTG MA. 17. J Natl Canc Inst 2005; 97:1262-1271. Updated results of the MA-17 showing an improvement in overall survival in the node-positive subset.
35. Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 2005; 23s:10s. Randomized trial providing evidence of DFS benefit for anastrozole in the extended adjuvant setting.
36. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23:619-629. A good review of published data for the adjuvant aromatase inhibitor trials and recommendations to incorporate aromatase inhibitors into the adjuvant treatment plan for postmenopausal women with hormone-receptor-positive early breast cancer.